| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T4 |
0-171 |
Sentence |
denotes |
Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. |
| T5 |
172-348 |
Sentence |
denotes |
Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. |
| T6 |
349-467 |
Sentence |
denotes |
Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. |
| T7 |
468-676 |
Sentence |
denotes |
Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. |
| T8 |
677-789 |
Sentence |
denotes |
Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. |
| T9 |
790-951 |
Sentence |
denotes |
The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]. |
